ORAL INHIBITORS OF PLATELET MEMBRANE-RECEPTOR GLYCOPROTEIN IIB IIIA IN CLINICAL CARDIOLOGY - ISSUES AND OPPORTUNITIES/

The feedback amplification loop in the progress of medicine, from basi c findings and clinical observations to hypothesis generation and new research, is presently particularly dynamic in acute coronary syndrome s. As the role of thrombosis formation in etiopathology of these syndr omes has emerged, antithrombotic therapy has become standard practice. Numerous trials with antiplatelet drugs and meta-analyses of these tr ials have established the efficacy of aspirin, launching new research in platelet physiology, understanding of pathophysiology, and therapy. Recognition of the role of glycoprotein IIb/IIIa receptor in health a nd disease and of its dynamic and ligands lead to production of a mono clonal antibody against the receptor, which has become the first anti- integrin therapy approved for clinical use. Synthetic compounds were s ubsequently produced containing the specific arginine-glycine-aspartic acid (RGD) sequence for fibrinogen binding to the receptor. Inhibitor s are now available for oral use, allowing prolonged blockade of the r eceptor and opportunities for new research and hypothesis generation a s well as better patient care. This supplement to the American Heart J ournal summarizes a workshop whose goal was to generate a discussion a mong fundamentalists and clinicians on methods for monitoring platelet function with these drugs and investigation of consequences of chroni c receptor occupancy.